Insights on Discovery
-
Advancing An Integrated Biopharma Workflow Strategy
1/30/2026
Global research teams were generating critical data in disconnected systems, hindering collaboration. Explore how unified workflows and a shared data backbone strengthen efficiency.
-
Enhancing Biopharma ROI With In-House Long-Read Sequencing
1/29/2026
Long-read sequencing is redefining research by enabling clearer insights into complex genetic regions. Learn how this technology strengthens data confidence and accelerates modern R&D workflows.
-
Enhancing Novel Developability Through Automated MS Analytics
1/29/2026
Growing biotherapeutic complexity demands MS workflows that can unify diverse datasets. Learn how automated approaches enhance data quality, streamline analysis, and support faster development.
-
Transforming Development Through Mass Spectrometry Data Analysis
1/29/2026
Mass spectrometry is vital for understanding PTMs in modern biologics. Explore key challenges and how streamlined analysis can reveal deeper, more sensitive insights into biotherapeutic structure.
-
End-To-End Workflow Integration For Antibody Development
1/29/2026
Modern antibody discovery generates massive, fragmented datasets that slow collaboration and decision‑making. Examine how unified digital workflows streamline R&D and improve data quality.
-
Overcoming Analytical Bottlenecks In Oligonucleotide Drug Development With Automation
1/29/2026
Growing oligonucleotide complexity is straining traditional analytical workflows. See how automated LC‑UV‑MS processing offers a scalable way to boost throughput and reduce manual effort.
-
Manufacturing of "MSC 2.0" Using Functionally Closed Systems
1/27/2026
Transitioning to closed systems enables the 100-fold expansion of engineered cells. Achieve high yields and maintain anti-cancer potency while reducing contamination risks and labor.
-
Spatial Organization Of The CAR Is Critical For CAR T Cell Function
1/27/2026
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
Psychiatric Drug Development Renaissance: With Familiar Risks
1/6/2026
Emerging psychiatric therapies bring hope, but progress is fragile. Biomarker-driven, mechanism-first approaches help overcome biological, regulatory, and commercial barriers.
-
A Strategic Overview Of Fc Engineering
1/5/2026
Explore how Fc engineering transforms antibodies into precise therapeutic tools by modulating immune effector functions and extending half-life to improve patient outcomes and overcome complex clinical challenges.